2 years ago

Ascend Gene & Cell Therapies Raises £105m in Series A to Advance Gene Therapy Manufacturing

  • London-based biotech firm Ascend Gene & Cell Therapies has raised £105.1 million in a Series A funding round led by Abingworth and Petrichor

  • The company, founded in 2021 by Monograph Capital, specializes in gene therapy manufacturing technology, assisting biotech companies in advancing their products to clinical trials

  • The funding will be used to support Ascend's growth and expansion, including the acquisition of Freeline Therapeutics' CMC capabilities and technologies for $25 million.

      • ProblemHealthcare

      "Gene therapy companies are struggling to build and maintain their own manufacturing capabilities, leading to inefficient use of resources and delays in bringing new therapies to market."

      Solution

      "Ascend Gene & Cell Therapies provides a comprehensive solution for gene therapy manufacturing, offering development, clinical manufacturing, analytics, and regulatory support. This allows companies to focus on their core research and development activities while leveraging Ascend's expertise and infrastructure."

      Covered on